Home/Pipeline/MediPrint Lens (Dry Eye)

MediPrint Lens (Dry Eye)

Dry Eye Disease

Pre-clinical/ResearchActive

Key Facts

Indication

Dry Eye Disease

Phase

Pre-clinical/Research

Status

Active

Company

MediPrint Ophthalmics

About MediPrint Ophthalmics

MediPrint Ophthalmics is a private, clinical-stage biotech company addressing significant unmet needs in ophthalmology through its proprietary MediPrint™ contact lens drug delivery platform. The company has completed a Phase 2a study and is advancing its lead glaucoma program into Phase 2b, with a pipeline targeting multi-billion dollar markets. With a clear path to Phase 3 data and a focus on non-invasive, patient-friendly therapies, MediPrint aims to establish a new standard of care in ocular drug delivery.

View full company profile

Therapeutic Areas

Glaucoma Dry Eye Disease Ocular Allergy

Other Dry Eye Disease Drugs

Drug	Company	Phase	Status
Elate Ocular®	Cambium Bio	Phase 3	Active
OT-301	Ocumension Therapeutics	Phase 2	Active
Avarept® Ophthalmic suspension 0.3%	Senju Pharmaceutical	Approved	Active
Dry Eye Care Portfolio	YD Bio	Commercial	Active
Dry Eye Studies	Oculus Research	Not Applicable (Service Provider)	Active
Tivanisiran	Sylentis	Phase 2/3	Active
A197	Aramis Biosciences	Phase 2	Active
KM102	Theratome Bio	Pre-clinical	Active
iTEAR®100 Commercialization	Olympic Ophthalmics	Commercial	Active
HydraD	EyeD Pharma	Pre-Clinical	Active
ST-100 (Vezocolmitide)	Stuart Therapeutics	Phase 3	Active
BRM421	BRIM Biotechnology	Phase 3	Active (Second Phase 3 trial application submitted 2025)